Sumitomo Pharma Co., Ltd.
Sumitomo Pharma Co., Ltd., a prominent player in the pharmaceutical preparation manufacturing industry, is headquartered in Japan. Established in 1897, the company has a rich history marked by significant milestones, including its expansion into global markets and a commitment to innovative healthcare solutions.
With a focus on research and development, Sumitomo Pharma excels in areas such as central nervous system disorders, oncology, and infectious diseases. Its core products are distinguished by their efficacy and safety, addressing critical health needs worldwide.
Recognised for its strong market position, Sumitomo Pharma continues to achieve notable advancements in drug development, contributing to improved patient outcomes. The company’s dedication to innovation and quality solidifies its reputation as a leader in the pharmaceutical industry.
-5 vs industry average
Sumitomo Pharma Co., Ltd.’s score of 33 is lower than 47% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Sumitomo Pharma Co., Ltd.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Emissions trajectory 2020 – 2026
Reported emissions
Scope 3 accounts for ••• of total emissions.
Sumitomo Pharma Co., Ltd.'s reported carbon emissions
Sumitomo Pharma Co., Ltd., a Japanese pharmaceutical manufacturer, reported a total of approximately 434.2 million kg CO2e in absolute emissions for fiscal year 2023. This figure comprises approximately 27.1 million kg CO2e for Scope 1 emissions, about 26.8 million kg CO2e for Scope 2 emissions, and approximately 356.2 million kg CO2e for Scope 3 emissions. The most significant contributor to their Scope 3 emissions was purchased goods and services, accounting for approximately 305 million kg CO2e.
For fiscal year 2022, Sumitomo Pharma recorded total emissions of approximately 446.9 million kg CO2e, with Scope 1 emissions around 27.8 million kg CO2e, Scope 2 emissions at approximately 26.5 million kg CO2e, and Scope 3 emissions totalling about 366.6 million kg CO2e.
In fiscal year 2021, the company's total emissions were approximately 464.0 million kg CO2e. This consisted of Scope 1 emissions of about 21.4 million kg CO2e, Scope 2 emissions of approximately 40.4 million kg CO2e, and Scope 3 emissions reaching about 382.3 million kg CO2e.
Sumitomo Pharma has established a commitment to reduce absolute Scope 1 and 2 greenhouse gas (GHG) emissions by 42% by fiscal year 2030, compared to a fiscal year 2020 baseline. Additionally, the company has committed to a 25% reduction in absolute Scope 3 GHG emissions from purchased goods and services within the same timeframe. These targets are validated by the Science Based Targets initiative (SBTi) as being consistent with keeping warming to 1.5°C.
Furthermore, there is a broader Group commitment to reduce CO2 emissions by 50% or more by 2035, compared to 2019 levels, encompassing Scope 1 and Scope 2 emissions. This long-term target is also an absolute reduction goal.
Emissions data for Sumitomo Pharma Co., Ltd. is directly reported by the company itself.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Sumitomo Pharma Co., Ltd.’s Climate Goals (2030 & 2050)
2 goals2035
50% reduction in Scope 1
Reduce the Group’s CO2 emissions 50% or more by 2035 (compared to 2019)
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 2 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
11 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Climate initiatives

Science Based Targets Initiative

Carbon Disclosure Project
Inherited from Sumitomo Chemical Company, LimitedThe Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisationsFrequently asked questions
Common questions about Sumitomo Pharma Co., Ltd.’s sustainability data and climate commitments
Data year: 2023
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project